Soft Tissue Sarcoma Pipeline Insight, 2020

 Breaking News
  • No posts were found

Soft Tissue Sarcoma Pipeline Insight, 2020

May 07
22:26 2020
Soft Tissue Sarcoma Pipeline Insight, 2020

DelveInsight Business Research LLP
“Soft Tissue Sarcoma Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Soft Tissue Sarcoma market. A detailed picture of the Soft Tissue Sarcoma pipeline landscape is provided, which includes the disease overview and Soft Tissue Sarcoma treatment guidelines.

Soft Tissue Sarcoma Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Soft Tissue Sarcoma market. A detailed picture of the Soft Tissue Sarcoma pipeline landscape is provided, which includes the disease overview and Soft Tissue Sarcoma treatment guidelines.

The assessment part of the report embraces in-depth Soft Tissue Sarcoma commercial assessment and clinical assessment of the Soft Tissue Sarcoma pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Soft Tissue Sarcoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The launch of the emerging therapies is expected to significantly impact Soft Tissue Sarcoma treatment scenario in the upcoming years:-

Drugs covered
1. Avapritinib (BLU-285)
2. Anlotinib (AL3818)
3. Selinexor
4. Aldoxorubicin (INNO-206)
5. Ripretinib (DCC-2618)
6. Fibromun (In combination with Doxorubicin)
7. Hensify (NBTXR3)
8. Crenolanib
9. TAS-116
10. GSK3377794
11. ADP-A2M4
12. Tazemetostat (EPZ-6438)
13. AMG 337
14. GB226/APL-501
15. Camsirubicin
And many others

The key players in Soft Tissue Sarcoma market are:
1. Blueprint Medicines Corporation
2. Advenchen Laboratories/Jiangsu Chia-Tai Tianqing Pharmaceutical
3. Karyopharm Therapeutics
4. Deciphera Pharmaceuticals
5. Philogen
6. GlaxoSmithKline
7. Epizyme
8. Eli Lilly and Company
9. Pfizer
10. Aadi Bioscience
11. Sierra Oncology
12. Nanobiotix
13. Taiho Oncology
14. Arog Pharmaceuticals
15. Merck Sharp & Dohme
And many others

Request for sample pages:

Table of contents:

1. Report Introduction

2. Soft Tissue Sarcoma 

2.1. Overview

2.2. History 

2.3. Soft Tissue Sarcoma Symptoms

2.4. Causes


2.6. Soft Tissue Sarcoma Diagnosis 

2.6.1. Diagnostic Guidelines

3. Soft Tissue Sarcoma Current Treatment Patterns

3.1. Soft Tissue Sarcoma Treatment Guidelines

4. Soft Tissue Sarcoma – DelveInsight’s Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Soft Tissue Sarcoma companies collaborations, Licensing, Acquisition -Deal Value Trends Assessment Summary

4.1.2. Soft Tissue Sarcoma Collaboration Deals Company-Company Collaborations (Licensing / Partnering) Analysis Company-University Collaborations (Licensing / Partnering) Analysis Soft Tissue Sarcoma Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs 

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination) Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA Assessment by Stage and MOA

5.1.6. Assessment by Target Assessment by Stage and Target

6. Soft Tissue Sarcoma Late Stage Products (Phase-III)

7. Soft Tissue Sarcoma Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Soft Tissue Sarcoma Discontinued Products

13. Soft Tissue Sarcoma Product Profiles

13.1. Drug Name: Company 

13.1.1. Product Description Product Overview Mechanism of action

13.1.2. Research and Development Clinical Studies

13.1.3. Product Development Activities Collaboration Agreements Acquisition Patent Detail

13.1.4. Tabulated Product Summary General Description Table

Detailed information in the report? 

14. Soft Tissue Sarcoma Key Companies

15. Soft Tissue Sarcoma Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products 

16.2.1. Reasons for the discontinuation

17. Soft Tissue Sarcoma Unmet Needs

18. Soft Tissue Sarcoma Future Perspectives

19. Soft Tissue Sarcoma Analyst Review  

20. Appendix

21. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation 

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States

Related Articles